Program
cebranopadol
Also written as “GRT6005”, “Cebranopadol” and “Cebranopadol 600 µg”.
Its studies are mostly in Pain · Chronic Pain · Acute Pain · Substance-Related Disorders · Osteoarthritis, led by 2 companies.
Drug pageCebranopadol: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tris Pharmaits history only | 160 open or running | phase 3since Oct 7, 2013 | Mar 24, 2009 | none ahead |
| Adneuris Therapeutics | 22 open or running | phase 3since Sep 22, 2026 | Sep 22, 2026 | Jan 2027phase 3 · NCT07845071 |
Also a collaborator on its studies: AbbVie.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Adneuris Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 22, 2026First study: phase 3 study in PainFirst studyNCT07845071 · 160 planned · United States
- Oct 8, 2026Phase 2 study in Chronic PainNCT07874620 · 45 planned · United States
Ahead
- Jan 2027Primary completion: phase 3 study in PainNCT07845071
- Mar 2027Primary completion: phase 2 study in Chronic PainNCT07874620
TargetBeta
“An orally available benzenoid that acts as an opioid peptide receptor agonist for the nociceptin/orphanin FQ peptide receptor (opioid receptor like -1; OPRL1; ORL-1; NOP; kappa-type 3 opioid receptor) and the classical opioid receptors, mu, delta and kappa, ”NCIt, by rule
“Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist”ChEMBL 37, by rule
Studies
All 2 Adneuris Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07874620Chronic Pain · United States | 2 | Recruiting | Mar 2027 | 45 |
| NCT07845071Pain · United States | 3 | Recruiting | Jan 2027 | 160 |
How it is read
Names in the registry
- “GRT6005”, 8 entries
- “Cebranopadol”, 5 entries
- “Cebranopadol 600 µg”, 3 entries
- “Cebranopadol 400 ug”, 2 entries
- “Cebranopadol 1000 µg”, 2 entries
Conditions, from the studies’ own filings
- Pain, 5 studies
- Chronic Pain, 3 studies
- Acute Pain, 2 studies
- Substance-Related Disorders, 1 study
- Osteoarthritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.